Rani Therapeutics Holdings Inc

Stock Chart, Company Information, and Scan Results

$2.63(as of Oct 20, 12:31 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Rani Therapeutics Holdings Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$2.63
Ticker SymbolRANI
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees105
CountyUSA
Market Cap$119.7M
EBIDTA-44.5M
10-Day Moving Average0.60
P/E Ratio-2.02
20-Day Moving Average0.55
Forward P/E Ratio0.00
50-Day Moving Average0.53
Earnings per Share-0.90
200-Day Moving Average0.91
Profit Margin-Infinity%
RSI92.99
Shares Outstanding47.9M
ATR0.17
52-Week High2.72
Volume489,317,900
52-Week Low0.39
Most Recent Support Level0.46
Book Value-9.2M
Most Recent Resistance Level0.50
P/B Ratio-6.55
Upper Keltner0.92
P/S Ratio49.94
Lower Keltner0.17
Debt-to-Equity Ratio0.92
Next Earnings Date11/12/2025
Cash Surplus-10.4M
Next Ex-Dividend DateUnknown

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Rani Therapeutics Holdings Inc In Our Stock Scanner

As of Oct 20, 2025
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Most Volatile StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.